EP
MXCT icon

Essential Partners’s MaxCyte MXCT Stock Holding History

Essential Partners’s Portfolio MXCT Stock Details MXCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$669 Sell
597
-1,518
-72% -$1.86K ﹤0.01% 2310
2026
Q2 		$2.6K Sell
2,115
-1,212
-36% -$1.21K ﹤0.01% 1865
2026
Q1 		$2.34K Buy
3,327
+1,579
+90% +$1.47K ﹤0.01% 1941
2025
Q4 		$2.71K Sell
1,748
-677
-28% -$1.08K ﹤0.01% 1696
2025
Q3 		$3.83K Buy
2,425
+2,258
+1,352% +$3.92K ﹤0.01% 1530
2025
Q2 		$364 Buy
+167
New +$404 ﹤0.01% 1786

Other funds holding MXCT

KL
KWMG LLC Overland Park, Kansas $1.39B AUM 24.28% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return
FFO
Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return

Essential Partners's MXCT Position: Q3 2026 in Review

Essential Partners reduced its MaxCyte (MXCT) stake by 72% in Q3 2026, selling an estimated $1.86K and leaving 597 shares worth $669. The position accounts for ﹤0.01% of the portfolio, ranked #2310.

Essential Partners first reported a position in MXCT in Q2 2025 and has held it in 6 quarters since. The position peaked at $3.83K in Q3 2025. 7 funds tracked by Wall St. Rank hold MXCT as of Q3 2026.

  • Essential Partners held 597 shares of MaxCyte worth $669 as of Q3 2026.
  • Essential Partners sold 1,518 MaxCyte shares in Q3 2026, an estimated $1.86K.
  • MaxCyte made up ﹤0.01% of Essential Partners's portfolio in Q3 2026, its #2310 holding.
  • Essential Partners first reported a position in MaxCyte in Q2 2025 and has held it in 6 quarters since.
  • Essential Partners's MaxCyte position peaked at $3.83K in Q3 2025.
  • 7 funds tracked by Wall St. Rank held MaxCyte as of Q3 2026.

Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.